Pub Date : 2023-09-21DOI: 10.4103/jcrt.jcrt_2701_22
Yaminy Pradeep Ingale, Sakshi Garg, Sushama Gurwale, Charusheela R. Gore
ABSTRACT Trichilemmal carcinoma (TC) is a rare, malignant, cutaneous adnexal neoplasm derived from the external root sheath of hair follicle, commonly seen in elderly males in the seventh to ninth decade. It commonly affects the sun-exposed areas and has an indolent course. We report a case of TC in which a 67-year-old female presented with a swelling on the scalp, which was misdiagnosed as a case of sebaceous cyst. The patient underwent excision and based on histopathological examination and immunohistochemistry, the diagnosis of TC was obtained.
{"title":"Trichilemmal carcinoma masquerading as a sebaceous cyst - A rare case report","authors":"Yaminy Pradeep Ingale, Sakshi Garg, Sushama Gurwale, Charusheela R. Gore","doi":"10.4103/jcrt.jcrt_2701_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2701_22","url":null,"abstract":"ABSTRACT Trichilemmal carcinoma (TC) is a rare, malignant, cutaneous adnexal neoplasm derived from the external root sheath of hair follicle, commonly seen in elderly males in the seventh to ninth decade. It commonly affects the sun-exposed areas and has an indolent course. We report a case of TC in which a 67-year-old female presented with a swelling on the scalp, which was misdiagnosed as a case of sebaceous cyst. The patient underwent excision and based on histopathological examination and immunohistochemistry, the diagnosis of TC was obtained.","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136235287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-21DOI: 10.4103/jcrt.jcrt_653_22
Sangeetha K. Nayanar, Anju Mohan, Praveen Shenoy, M Saravanan, Vipin Gopinath, V. G Deepak Roshan
ABSTRACT Background and Objectives: Epidermal growth factor receptor (EGFR) mutation analysis has become an important part of the initial workup of non-squamous non-small cell lung cancer (NS-NSCLC) patients. This study is attempted as South Indians population is comprised of ethnic groups with diverse genetic makeup and only very limited data on EGFR mutation is available from south India. A detailed understanding of EGFR mutation profile will help in better planning of treatment strategies and resource allocation. Methods: A retrospective analysis of EGFR mutation frequency in 350 patients diagnosed with adenocarcinoma of lung and its association with pathological characteristics was done. Results: Out of 350 cases of pulmonary adenocarcinoma, within an age group ranging from 30 to 86 years. EGFR mutations were identified in 34.8% (n = 122) cases, out of which 35.24% (n = 43) were in non-smoker females ( P = 0.001). Of the 14 cases with resistant type of EGFR mutations, nine were in smoker males and the remaining five in non-smoker females. Interpretation and Conclusion: Overall EGFR mutation frequency observed in our study was similar to other Indian studies. However, in our study, we observed that mutation in exon 21 was less frequent compared to other studies. A similar slightly increased frequency of rare mutations and double mutations were observed in our study. A detailed study of the molecular epidemiology of lung cancer and its association with different geographical zones of India is needed. This understanding will help in better planning of treatment strategies and resource allocation.
{"title":"Frequency of EGFR mutations in lung adenocarcinoma patients – A study from tertiary cancer center of South India","authors":"Sangeetha K. Nayanar, Anju Mohan, Praveen Shenoy, M Saravanan, Vipin Gopinath, V. G Deepak Roshan","doi":"10.4103/jcrt.jcrt_653_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_653_22","url":null,"abstract":"ABSTRACT Background and Objectives: Epidermal growth factor receptor (EGFR) mutation analysis has become an important part of the initial workup of non-squamous non-small cell lung cancer (NS-NSCLC) patients. This study is attempted as South Indians population is comprised of ethnic groups with diverse genetic makeup and only very limited data on EGFR mutation is available from south India. A detailed understanding of EGFR mutation profile will help in better planning of treatment strategies and resource allocation. Methods: A retrospective analysis of EGFR mutation frequency in 350 patients diagnosed with adenocarcinoma of lung and its association with pathological characteristics was done. Results: Out of 350 cases of pulmonary adenocarcinoma, within an age group ranging from 30 to 86 years. EGFR mutations were identified in 34.8% (n = 122) cases, out of which 35.24% (n = 43) were in non-smoker females ( P = 0.001). Of the 14 cases with resistant type of EGFR mutations, nine were in smoker males and the remaining five in non-smoker females. Interpretation and Conclusion: Overall EGFR mutation frequency observed in our study was similar to other Indian studies. However, in our study, we observed that mutation in exon 21 was less frequent compared to other studies. A similar slightly increased frequency of rare mutations and double mutations were observed in our study. A detailed study of the molecular epidemiology of lung cancer and its association with different geographical zones of India is needed. This understanding will help in better planning of treatment strategies and resource allocation.","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"191 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136235432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-21DOI: 10.4103/jcrt.jcrt_1603_20
Suvendu Maji, Saurav K. Ghosh, Jayesh K. Jha, Vikram Chaturvedi
ABSTRACT Background: Multiple primary cancers once thought to be rare have become increasingly common as the lifespan of cancer survivors has increased with availability of better and more effective cancer treatment. However, their exact incidence is not known and data on their epidemiological characteristics are not available. Aim: The aim of this study is to study the epidemiologic characteristics of multiple primary cancers in the eastern region of India. Materials and Method: The study was conducted in the Department of Surgical Oncology, Medical College, Kolkata, from 2017 to 2020 over a period of 3 years. All patients with a diagnosis of second primary as per International Agency for Research on Cancer (IARC) definition or those developing a second primary within the study period were included for analysis. Data were recorded in form of preformed questionnaires. All the cases were followed up for at least 12 months. Result: Fifty cases of multiple primary tumors were identified, out of which 21 were synchronous while rest 29 were metachronous type. The male–female ratio was 1:1.2. The median age at presentation for index malignancy was 50 years. The most common malignancy in the synchronous group was a combination of variety of GI cancers (six cases). In the metachronous category, a combination of reproductive cancers (breast, ovary, cervix, and endometrium) along with Gastrointestinal cancer (GI) cancers (colon, rectum) was most frequently found (eight cases). Definite risk factors for multiple primary tumors were identifiable in 10 cases: arsenic exposure in 5 cases, hereditary in 4 cases, and immunosuppression in 1, while in 8 cases, risk factors were only speculative (radiation 5 cases, chemotherapy 3). At the time of the last follow-up, 36 subjects were alive and 3 dead while the status of 11 subjects was unknown. Conclusion: This is the first comprehensive study on multiple primary cancers and the largest so far in India. Our study overcomes the shortcoming of previous case series from our subcontinent. The merits of our study include the use of the most accepted IARC definition, updated staging guidelines with long follow-up, and reliable survival data. Additionally, we could identify risk factors in 50% of our subjects. And our study shows various new combinations of cancers not reported before. Clustering of cases in the young adolescent group (25–49) years is also a new finding. We also highlight the existing ambiguity in the way this entity is defined. Demerits include the loss of follow-up data in a significant number of patients.
{"title":"A prospective observational study to assess the epidemiological profile of multiple primary cancers in Eastern India","authors":"Suvendu Maji, Saurav K. Ghosh, Jayesh K. Jha, Vikram Chaturvedi","doi":"10.4103/jcrt.jcrt_1603_20","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1603_20","url":null,"abstract":"ABSTRACT Background: Multiple primary cancers once thought to be rare have become increasingly common as the lifespan of cancer survivors has increased with availability of better and more effective cancer treatment. However, their exact incidence is not known and data on their epidemiological characteristics are not available. Aim: The aim of this study is to study the epidemiologic characteristics of multiple primary cancers in the eastern region of India. Materials and Method: The study was conducted in the Department of Surgical Oncology, Medical College, Kolkata, from 2017 to 2020 over a period of 3 years. All patients with a diagnosis of second primary as per International Agency for Research on Cancer (IARC) definition or those developing a second primary within the study period were included for analysis. Data were recorded in form of preformed questionnaires. All the cases were followed up for at least 12 months. Result: Fifty cases of multiple primary tumors were identified, out of which 21 were synchronous while rest 29 were metachronous type. The male–female ratio was 1:1.2. The median age at presentation for index malignancy was 50 years. The most common malignancy in the synchronous group was a combination of variety of GI cancers (six cases). In the metachronous category, a combination of reproductive cancers (breast, ovary, cervix, and endometrium) along with Gastrointestinal cancer (GI) cancers (colon, rectum) was most frequently found (eight cases). Definite risk factors for multiple primary tumors were identifiable in 10 cases: arsenic exposure in 5 cases, hereditary in 4 cases, and immunosuppression in 1, while in 8 cases, risk factors were only speculative (radiation 5 cases, chemotherapy 3). At the time of the last follow-up, 36 subjects were alive and 3 dead while the status of 11 subjects was unknown. Conclusion: This is the first comprehensive study on multiple primary cancers and the largest so far in India. Our study overcomes the shortcoming of previous case series from our subcontinent. The merits of our study include the use of the most accepted IARC definition, updated staging guidelines with long follow-up, and reliable survival data. Additionally, we could identify risk factors in 50% of our subjects. And our study shows various new combinations of cancers not reported before. Clustering of cases in the young adolescent group (25–49) years is also a new finding. We also highlight the existing ambiguity in the way this entity is defined. Demerits include the loss of follow-up data in a significant number of patients.","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136236053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABSTRACT Background: Skin appendageal tumors (SAT) are a rare group of tumors that are classified according to their line of appendageal differentiation along eccrine, apocrine, follicular, and sebaceous lines. However, they are relatively uncommon and create diagnostic difficulties for the pathologist. Recognition of malignant transformation adds to the importance of an accurate diagnosis. A paucity of clinicopathological data from the Himalayan region of India, in particular, prompted the conduct of this study. Aim: To study the clinical and histopathological spectrum of SAT during a period of 1 year received at our hospital. Materials and Methods: A retrospective study was carried out at the Pathology department of our hospital. All relevant clinical characteristics were noted in addition to the histopathological features. Slides stained with both hematoxylin and eosin and special stains where necessary were used to supplement the diagnoses. Results: A total of 17 cases were diagnosed in 1 year (January 2021 to December 2021) at our institute. The predominant age group was 40–59 years. Females outnumbered males, with a male: female ratio of 0.8:1. The most common location of tumors was in the head and neck (90.90%). The majority of cases were benign (90.90%). The majority of tumors were of follicular differentiation (54.55%). We found one malignant tumor of sebaceous differentiation. Conclusion: The clinical presentation is remarkably similar to most SAT. In our study, we found that majority of tumors were benign and located in the head and neck. The importance of an accurate histopathological diagnosis is essential in these tumors to diagnose the malignant counterparts and differentiate them from more common skin tumors with different prognoses.
{"title":"Skin appendageal tumors: A 1 year data from a tertiary care institute","authors":"Mamta Thakur, Lekshmi Vijayamohanan, Sarita Asotra","doi":"10.4103/jcrt.jcrt_174_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_174_22","url":null,"abstract":"ABSTRACT Background: Skin appendageal tumors (SAT) are a rare group of tumors that are classified according to their line of appendageal differentiation along eccrine, apocrine, follicular, and sebaceous lines. However, they are relatively uncommon and create diagnostic difficulties for the pathologist. Recognition of malignant transformation adds to the importance of an accurate diagnosis. A paucity of clinicopathological data from the Himalayan region of India, in particular, prompted the conduct of this study. Aim: To study the clinical and histopathological spectrum of SAT during a period of 1 year received at our hospital. Materials and Methods: A retrospective study was carried out at the Pathology department of our hospital. All relevant clinical characteristics were noted in addition to the histopathological features. Slides stained with both hematoxylin and eosin and special stains where necessary were used to supplement the diagnoses. Results: A total of 17 cases were diagnosed in 1 year (January 2021 to December 2021) at our institute. The predominant age group was 40–59 years. Females outnumbered males, with a male: female ratio of 0.8:1. The most common location of tumors was in the head and neck (90.90%). The majority of cases were benign (90.90%). The majority of tumors were of follicular differentiation (54.55%). We found one malignant tumor of sebaceous differentiation. Conclusion: The clinical presentation is remarkably similar to most SAT. In our study, we found that majority of tumors were benign and located in the head and neck. The importance of an accurate histopathological diagnosis is essential in these tumors to diagnose the malignant counterparts and differentiate them from more common skin tumors with different prognoses.","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"97 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136236041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
ABSTRACT Background: Low-grade appendiceal mucinous neoplasms (LAMNs) are benign non-invasive epithelial proliferations of the appendix. These usually present clinically as mucoceles and these rarely exceed 2 cm in diameter. Lesions confined to the lumen are labelled as LAMN; however those in which mucin spreads outside the peritoneum are labeled as pseudomyxoma peritonei (PMP). Aims and Objective: A retrospective study was conducted over a period of three years and all cases of appendectomies were studied. Twelve cases of LAMN were identified, which is a diagnostic dilemma for the pathologists and clinicians. Results: LAMN was identified based on the histopathological features. Out of the 12 cases, 9 were classified as LAMN and 3 as appendiceal neoplasm with PMP. There was villous or flat proliferation of epithelial lining, loss lymphoid aggregates, and dissecting mucin within muscularis. Conclusion: LAMNs are rare neoplasms of the appendix, with clinical presentation similar to acute appendicitis. Mucinous collections within the appendiceal wall should be extensively searched for mucosal changes and, if found, should prompt a careful search for pushing invasion of LAMNs. A thorough and vigilant gross examination can be of great help. Appendicectomy is the treatment of benign and grossly intact mucinous neoplasm.
{"title":"Low-grade appendiceal mucinous neoplasms: Histomorphological spectrum in a tertiary care hospital","authors":"Manisha Ahuja, Shramana Mandal, Varuna Mallya, Meeta Singh, Nita Khurana, Pawanindra Lal","doi":"10.4103/jcrt.jcrt_149_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_149_22","url":null,"abstract":"ABSTRACT Background: Low-grade appendiceal mucinous neoplasms (LAMNs) are benign non-invasive epithelial proliferations of the appendix. These usually present clinically as mucoceles and these rarely exceed 2 cm in diameter. Lesions confined to the lumen are labelled as LAMN; however those in which mucin spreads outside the peritoneum are labeled as pseudomyxoma peritonei (PMP). Aims and Objective: A retrospective study was conducted over a period of three years and all cases of appendectomies were studied. Twelve cases of LAMN were identified, which is a diagnostic dilemma for the pathologists and clinicians. Results: LAMN was identified based on the histopathological features. Out of the 12 cases, 9 were classified as LAMN and 3 as appendiceal neoplasm with PMP. There was villous or flat proliferation of epithelial lining, loss lymphoid aggregates, and dissecting mucin within muscularis. Conclusion: LAMNs are rare neoplasms of the appendix, with clinical presentation similar to acute appendicitis. Mucinous collections within the appendiceal wall should be extensively searched for mucosal changes and, if found, should prompt a careful search for pushing invasion of LAMNs. A thorough and vigilant gross examination can be of great help. Appendicectomy is the treatment of benign and grossly intact mucinous neoplasm.","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136236042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-21DOI: 10.4103/jcrt.jcrt_2566_22
Ahmed Al Qteishat, Raisa Aringazina, Dmitriy Ermakov, Elena Demianenko
ABSTRACT Context: Breast cancer is the most common diagnosis established in women with malignant tumors. Aims: The purpose is to investigate the blood contents of adiponectin and leptin in women with breast cancer and obesity. Settings and Design: A total of 140 women aged 40–50 were examined. Materials and Methods: Group 1 included 70 women from classes 1 or 2 obesity. Group 2 included 70 women with stage 1 or 2 breast cancer and classes 1 or 2 obesity. The control group included 30 apparently healthy women, with mean age of 42.5 ± 2.5 years. Statistical Analysis Used: Statistical processing of the results obtained was performed using Statistica. Results: Groups 1 and 2 were statistically significantly different from each other across all parameters, except for leptin resistance. In group 2, the course of breast cancer with concomitant obesity is characterized by disrupted adipocytokine homeostasis, which manifests as a 1.94-fold decrease in the blood content of adiponectin ( P < 0.05), a 4.14-fold increase in the blood content of leptin ( P < 0.05), and an 8.00-fold increase in the leptin/adiponectin ratio ( P < 0.05). Poorly differentiated breast tumors exhibit a more pronounced imbalance in the blood levels of adipocytokines. Thus, the serum content of leptin in women with poorly differentiated tumors (G3) was 1.79 times ( P < 0.05) higher than in women with moderately differentiated tumors (G2). Conclusions: The course of breast cancer with concomitant obesity is characterized by disrupted adipocytokine homeostasis and decreased adiponectin concentration in the blood.
{"title":"Adipocytokine imbalance and breast cancer in obese women","authors":"Ahmed Al Qteishat, Raisa Aringazina, Dmitriy Ermakov, Elena Demianenko","doi":"10.4103/jcrt.jcrt_2566_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2566_22","url":null,"abstract":"ABSTRACT Context: Breast cancer is the most common diagnosis established in women with malignant tumors. Aims: The purpose is to investigate the blood contents of adiponectin and leptin in women with breast cancer and obesity. Settings and Design: A total of 140 women aged 40–50 were examined. Materials and Methods: Group 1 included 70 women from classes 1 or 2 obesity. Group 2 included 70 women with stage 1 or 2 breast cancer and classes 1 or 2 obesity. The control group included 30 apparently healthy women, with mean age of 42.5 ± 2.5 years. Statistical Analysis Used: Statistical processing of the results obtained was performed using Statistica. Results: Groups 1 and 2 were statistically significantly different from each other across all parameters, except for leptin resistance. In group 2, the course of breast cancer with concomitant obesity is characterized by disrupted adipocytokine homeostasis, which manifests as a 1.94-fold decrease in the blood content of adiponectin ( P < 0.05), a 4.14-fold increase in the blood content of leptin ( P < 0.05), and an 8.00-fold increase in the leptin/adiponectin ratio ( P < 0.05). Poorly differentiated breast tumors exhibit a more pronounced imbalance in the blood levels of adipocytokines. Thus, the serum content of leptin in women with poorly differentiated tumors (G3) was 1.79 times ( P < 0.05) higher than in women with moderately differentiated tumors (G2). Conclusions: The course of breast cancer with concomitant obesity is characterized by disrupted adipocytokine homeostasis and decreased adiponectin concentration in the blood.","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"42 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136235282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-21DOI: 10.4103/jcrt.jcrt_1747_22
Sumit Agarwal, Isha Jaiswal, Uday P. Shahi, Abhijit Mandal, Lalit M. Aggarwal, Ankita Singh, Anil Jaiswal, Nandlal Yadawa
ABSTRACT Purpose: To assess the role of Accelerated Hypofractionated Chemoradiation for Locally Advanced Head & Neck squamous cell cancer (HNSCC) during COVID 19 pandemic. Materials and Methods: Previously untreated 20 patients with locally advanced HNSCC (Oral cavity/oropharynx/larynx/hypopharynx) were treated with definitive hypofractionated radiotherapy of 60Gy in 25 fractions with concurrent cisplatin @35 mg/m 2 once weekly for 5 weeks from March 2020 to November 2021. The patients were treated on 6MV LINAC with Volumetric modulated arc therapy (VMAT) by the Sequential boost technique and concurrent chemotherapy @35 mg/m 2 . All the patients received 48Gy in 20 fractions to low-risk volume (CTV LR) in Phase I followed by 12Gy in 5 fractions boost to High-risk volume (CTV HR) in Phase II. The organs at risk (OARs) were contoured and appropriate constraints were given considering the hypofractionated regimen. Results: Out of 20 patients, most of the patients were Stage IV (15;75%) & stage III 20%, out of which (55%) 11 were of the oral cavity, (40%) 8 were of the oropharynx, and (5%) 1 of larynx. All patients were treated with 60Gy/25#/5 weeks with the majority of the patients (17;85%) completing their treatment in less than 45 days. The Median follow-up was of 214 days. The locoregional control at 6 Months was 55%. Maximum acute toxicity was grade 3 mucositis which was observed in 18 (90%) patients. Ryle’s tube feeding was needed in 11 (55%) patient. Out of 20 patients, 5 patients did not receive concurrent chemotherapy, and 8 (40%) patients received all 5 cycles of chemotherapy. 7, 35% of the patients could not complete all 5 cycles of concurrent chemotherapy due to grade 3 mucositis. Conclusion: During a pandemic crisis with limited manpower & technical resources accelerated hypofractionated radiotherapy with concurrent chemotherapy can be considered a feasible therapeutic option for HNSCC which can significantly reduce the overall Treatment Time (OTT) with comparable local control and manageable toxicities.
{"title":"Accelerated hypofractionated chemoradiation for locally advanced head and neck cancer during COVID 19 pandemic: A tertiary care experience","authors":"Sumit Agarwal, Isha Jaiswal, Uday P. Shahi, Abhijit Mandal, Lalit M. Aggarwal, Ankita Singh, Anil Jaiswal, Nandlal Yadawa","doi":"10.4103/jcrt.jcrt_1747_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1747_22","url":null,"abstract":"ABSTRACT Purpose: To assess the role of Accelerated Hypofractionated Chemoradiation for Locally Advanced Head & Neck squamous cell cancer (HNSCC) during COVID 19 pandemic. Materials and Methods: Previously untreated 20 patients with locally advanced HNSCC (Oral cavity/oropharynx/larynx/hypopharynx) were treated with definitive hypofractionated radiotherapy of 60Gy in 25 fractions with concurrent cisplatin @35 mg/m 2 once weekly for 5 weeks from March 2020 to November 2021. The patients were treated on 6MV LINAC with Volumetric modulated arc therapy (VMAT) by the Sequential boost technique and concurrent chemotherapy @35 mg/m 2 . All the patients received 48Gy in 20 fractions to low-risk volume (CTV LR) in Phase I followed by 12Gy in 5 fractions boost to High-risk volume (CTV HR) in Phase II. The organs at risk (OARs) were contoured and appropriate constraints were given considering the hypofractionated regimen. Results: Out of 20 patients, most of the patients were Stage IV (15;75%) & stage III 20%, out of which (55%) 11 were of the oral cavity, (40%) 8 were of the oropharynx, and (5%) 1 of larynx. All patients were treated with 60Gy/25#/5 weeks with the majority of the patients (17;85%) completing their treatment in less than 45 days. The Median follow-up was of 214 days. The locoregional control at 6 Months was 55%. Maximum acute toxicity was grade 3 mucositis which was observed in 18 (90%) patients. Ryle’s tube feeding was needed in 11 (55%) patient. Out of 20 patients, 5 patients did not receive concurrent chemotherapy, and 8 (40%) patients received all 5 cycles of chemotherapy. 7, 35% of the patients could not complete all 5 cycles of concurrent chemotherapy due to grade 3 mucositis. Conclusion: During a pandemic crisis with limited manpower & technical resources accelerated hypofractionated radiotherapy with concurrent chemotherapy can be considered a feasible therapeutic option for HNSCC which can significantly reduce the overall Treatment Time (OTT) with comparable local control and manageable toxicities.","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136236189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-21DOI: 10.4103/jcrt.jcrt_2238_22
Seher Nazlı Kazaz, Atila Yıldırım
ABSTRACT Background: The aim of the study was to measure the adherence to oral anticancer treatments in cancer patients using the Modified Morisky Scale (Modified Medication Adherence Scale 6) which has been shown to be valid and reliable in Turkish. Methods: This study was an observational, single-center study involving 300 cancer patients receiving various oral anticancer agents admitted to our outpatient clinic. Motivation and knowledge scores were calculated as per the Modified Medication Adherence Scale 6. Results: The motivation and knowledge levels of the population aged less than 65 years were found to be significantly higher than the geriatric population (≥65 years old) ( P < .003 and P< .001, respectively). It was observed that the patients with higher education levels had significantly higher motivation and knowledge levels ( P < .0001 for both). There was no correlation between the motivation and knowledge levels of the patients with gender, marital status, living status, and stage of the disease ( P > .05). In addition, the duration of drug use >12 months and the cyclical use of drugs were also found to be significantly associated with increased motivation and knowledge levels. Conclusion: Identifying adherence and related factors, informing patients in detail about the efficacy and toxicity of treatments are the simplest and most basic methods. Particular attention should be paid to patients aged > 65 years, patients with a low level of education, and patients in the earlier stages of their treatments.
{"title":"Evaluation of patient adherence with oral anticancer agents","authors":"Seher Nazlı Kazaz, Atila Yıldırım","doi":"10.4103/jcrt.jcrt_2238_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2238_22","url":null,"abstract":"ABSTRACT Background: The aim of the study was to measure the adherence to oral anticancer treatments in cancer patients using the Modified Morisky Scale (Modified Medication Adherence Scale 6) which has been shown to be valid and reliable in Turkish. Methods: This study was an observational, single-center study involving 300 cancer patients receiving various oral anticancer agents admitted to our outpatient clinic. Motivation and knowledge scores were calculated as per the Modified Medication Adherence Scale 6. Results: The motivation and knowledge levels of the population aged less than 65 years were found to be significantly higher than the geriatric population (≥65 years old) ( P < .003 and P< .001, respectively). It was observed that the patients with higher education levels had significantly higher motivation and knowledge levels ( P < .0001 for both). There was no correlation between the motivation and knowledge levels of the patients with gender, marital status, living status, and stage of the disease ( P > .05). In addition, the duration of drug use >12 months and the cyclical use of drugs were also found to be significantly associated with increased motivation and knowledge levels. Conclusion: Identifying adherence and related factors, informing patients in detail about the efficacy and toxicity of treatments are the simplest and most basic methods. Particular attention should be paid to patients aged > 65 years, patients with a low level of education, and patients in the earlier stages of their treatments.","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136236038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.4103/jcrt.jcrt_919_23
Yan Zhang, Qiao Zhang, Yingying Zheng, Jiaxi Chen, Nian Liu, Kai Liu, Wengang Song
Background: Hashimoto's thyroiditis (HT) is an independent risk factor for papillary thyroid carcinoma (PTC), but the underlying mechanism remains unknown. The incidence of PTC in patients with HT is significantly elevated, and the presence of both HT and PTC contributes to a higher rate of misdiagnosis.
Materials and methods: Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed on the thyroid nodule gene chip dataset from GEO Datasets. Serum and clinical data from 191 patients with thyroid nodules at the affiliated hospital were collected for analysis. Experimental techniques, including real-time quantitative PCR, ELISA, immunohistochemistry (IHC), and enzyme activity detection, were used to measure the level of dipeptidyl peptidase 4 (DPP4) in thyroid nodule tissues and serum.
Results: Thyroid nodules in patients with HT and PTC exhibit high levels of DPP4, along with elevated concentrations of soluble DPP4 in the serum. These findings demonstrate the potential predictive value of soluble DPP4 for PTC diagnosis.
Conclusions: The concentration and enzymatic activity of soluble DPP4 in serum can serve as diagnostic biomarkers for patients with HT-associated PTC.
{"title":"Soluble DPP4 can act as a diagnostic biomarker in Hashimoto's thyroiditis with thyroid papillary carcinoma.","authors":"Yan Zhang, Qiao Zhang, Yingying Zheng, Jiaxi Chen, Nian Liu, Kai Liu, Wengang Song","doi":"10.4103/jcrt.jcrt_919_23","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_919_23","url":null,"abstract":"<p><strong>Background: </strong>Hashimoto's thyroiditis (HT) is an independent risk factor for papillary thyroid carcinoma (PTC), but the underlying mechanism remains unknown. The incidence of PTC in patients with HT is significantly elevated, and the presence of both HT and PTC contributes to a higher rate of misdiagnosis.</p><p><strong>Materials and methods: </strong>Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed on the thyroid nodule gene chip dataset from GEO Datasets. Serum and clinical data from 191 patients with thyroid nodules at the affiliated hospital were collected for analysis. Experimental techniques, including real-time quantitative PCR, ELISA, immunohistochemistry (IHC), and enzyme activity detection, were used to measure the level of dipeptidyl peptidase 4 (DPP4) in thyroid nodule tissues and serum.</p><p><strong>Results: </strong>Thyroid nodules in patients with HT and PTC exhibit high levels of DPP4, along with elevated concentrations of soluble DPP4 in the serum. These findings demonstrate the potential predictive value of soluble DPP4 for PTC diagnosis.</p><p><strong>Conclusions: </strong>The concentration and enzymatic activity of soluble DPP4 in serum can serve as diagnostic biomarkers for patients with HT-associated PTC.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 4","pages":"1048-1054"},"PeriodicalIF":1.3,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10178885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-08-01DOI: 10.4103/jcrt.jcrt_2711_22
YuBin Zhou, Jian Huang, Jun Lan, Hao Hu, Zihao Yuan, Longyan Dong, Huiyin Deng, Li-Ao Yue, Yi Xiao, Xiongwen Yang
Background: Compared with other lung squamous cell carcinomas (LUSC), pulmonary lymphoepithelioma-like carcinoma (pLELC) is closely associated with Epstein-Barr virus (EBV) infections with a unique molecular profile and immune microenvironment. This study was thus established to compare the treatment response and effectiveness of immunotherapy between pLELC and LUSC.
Material and methods: We enrolled 31 patients with pLELC and 116 with LUSC receiving first-line immunotherapy at three centers in China and compared the treatment response and effectiveness of immunotherapy. Propensity score matching (PSM) was used to balance the differences in baseline data between the two groups.
Results: Before PSM, progression-free survival and overall survival were longer in the pLELC group than in the LUSC group (progression-free survival: hazard ratio (HR), 1.67, 95% CI: 1.05-2.63, P = 0.028; overall survival: HR, 1.90, 95% CI: 1.06-3.40, P = 0.028). This remained unchanged after PSM (progression-free survival: HR, 1.79, 95% CI: 1.02-3.15, P = 0.044; overall survival: HR, 2.20; 95% CI: 1.10-4.37, P = 0.022).
Conclusion: pLELC showed a clinically meaningful survival benefit compared with traditional LUSC following immunotherapy. Subsequent studies should consider the role of the EBV in the tumor immune microenvironment of pLELC.
背景:与其他肺鳞状细胞癌(LUSC)相比，肺淋巴上皮瘤样癌(pLELC)具有独特的分子特征和免疫微环境，与eb病毒(EBV)感染密切相关。因此，本研究旨在比较pLELC和LUSC的治疗反应和免疫治疗的有效性。材料和方法:我们在中国的三个中心招募了31例pLELC患者和116例LUSC患者接受一线免疫治疗，并比较了免疫治疗的治疗反应和有效性。使用倾向评分匹配(PSM)来平衡两组之间基线数据的差异。结果:PSM前，pLELC组的无进展生存期和总生存期均长于LUSC组(无进展生存期:风险比(HR)， 1.67, 95% CI: 1.05 ~ 2.63, P = 0.028;总生存率:HR, 1.90, 95% CI: 1.06-3.40, P = 0.028)。PSM后这一情况保持不变(无进展生存期:HR, 1.79, 95% CI: 1.02-3.15, P = 0.044;总生存期:HR, 2.20;95% ci: 1.10-4.37, p = 0.022)。结论:与传统LUSC相比，pLELC在免疫治疗后具有临床意义的生存获益。后续研究应考虑EBV在pLELC肿瘤免疫微环境中的作用。
{"title":"Comparison of first-line immunotherapy efficacy between advanced lung squamous cell carcinoma and pulmonary lymphoepithelioma-like carcinoma: A propensity score matching multicenter study.","authors":"YuBin Zhou, Jian Huang, Jun Lan, Hao Hu, Zihao Yuan, Longyan Dong, Huiyin Deng, Li-Ao Yue, Yi Xiao, Xiongwen Yang","doi":"10.4103/jcrt.jcrt_2711_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2711_22","url":null,"abstract":"<p><strong>Background: </strong>Compared with other lung squamous cell carcinomas (LUSC), pulmonary lymphoepithelioma-like carcinoma (pLELC) is closely associated with Epstein-Barr virus (EBV) infections with a unique molecular profile and immune microenvironment. This study was thus established to compare the treatment response and effectiveness of immunotherapy between pLELC and LUSC.</p><p><strong>Material and methods: </strong>We enrolled 31 patients with pLELC and 116 with LUSC receiving first-line immunotherapy at three centers in China and compared the treatment response and effectiveness of immunotherapy. Propensity score matching (PSM) was used to balance the differences in baseline data between the two groups.</p><p><strong>Results: </strong>Before PSM, progression-free survival and overall survival were longer in the pLELC group than in the LUSC group (progression-free survival: hazard ratio (HR), 1.67, 95% CI: 1.05-2.63, P = 0.028; overall survival: HR, 1.90, 95% CI: 1.06-3.40, P = 0.028). This remained unchanged after PSM (progression-free survival: HR, 1.79, 95% CI: 1.02-3.15, P = 0.044; overall survival: HR, 2.20; 95% CI: 1.10-4.37, P = 0.022).</p><p><strong>Conclusion: </strong>pLELC showed a clinically meaningful survival benefit compared with traditional LUSC following immunotherapy. Subsequent studies should consider the role of the EBV in the tumor immune microenvironment of pLELC.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 4","pages":"1011-1018"},"PeriodicalIF":1.3,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10183884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：